Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Integrated multiclass driver ctDNA profiling enables MPNST detection and monitoring in NF1 patients.

NPJ precision oncology·2026
Same author

Harmonizing standards and resources for the medical genome.

Nature·2026
Same author

Structured reasoning failures compromise LLM interpretation of clinical oncology notes.

NPJ digital medicine·2026
Same author

Spatial and multi-omic profiling reveals pericyte-derived CCL19 as a key prognostic factor in CNS lymphoma.

HemaSphere·2026
Same author

Evaluation of Baseline and Interim-Therapy PET Features for Prognostication in High-Risk Pediatric Hodgkin Lymphoma: A Retrospective Analysis of the AHOD1331 Trial.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Are There CT Imaging Features That Can Distinguish Primary Pulmonary Squamous Cell Carcinoma from Solitary Lung Metastasis of Head and Neck Squamous Cell Carcinoma?

Cancers·2026

相关实验视频

Updated: Jun 14, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.2K

从免疫检查点抑制中早期识别治疗益处

Barzin Y Nabet1, Mohammad S Esfahani2, Everett J Moding1

  • 1Department of Radiation Oncology, Stanford University, Stanford, CA, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, USA.

Cell
|October 2, 2020
PubMed
概括
此摘要是机器生成的。

在接受免疫检查点抑制剂 (ICI) 治疗的非小细胞肺癌 (NSCLC) 患者中预测持久的临床益处具有挑战性. 一种新型的非侵入性检测方法, 结合循环瘤DNA (ctDNA) 和免疫细胞分析, 准确预测患者的早期结果.

关键词:
循环中的瘤DNA免疫检查点抑制免疫疗法液体活检其他非小细胞肺癌响应分类

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.0K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.4K

相关实验视频

Last Updated: Jun 14, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.2K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.0K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.4K

科学领域:

  • 癌症学
  • 免疫疗法
  • 分子诊断

背景情况:

  • 免疫检查点抑制剂 (ICI) 在非小细胞肺癌 (NSCLC) 中提供持久反应,但大多数患者会出现早期进展.
  • 传统的成像在预测ICI的持续性临床益处方面缺乏准确性.
  • 确定可能受益于ICI的患者仍然是一个关键的未满足需求.

研究的目的:

  • 在接受ICI的NSCLC患者中确定预测持久临床益处的非侵入性生物标志物.
  • 开发和验证多参数试验,以预测早期和准确的结果.

主要方法:

  • 治疗前循环瘤DNA (ctDNA) 和外围CD8T细胞水平的分析.
  • 在第一次ICI输液后监测ctDNA动态.
  • 开发和验证集成这些生物标志物的非侵入性DIREct-On测试.

主要成果:

  • 治疗前的ctDNA和CD8T细胞水平与DCB独立相关.
  • 输注后的ctDNA动态进一步有助于识别患有DCB的患者.
  • 综合的DIREct-On试验在预测DCB方面比单个标志物更准确.

结论:

  • 综合性ctDNA和免疫细胞分析为ICI患者提供准确,非侵入性和早期预测结果.
  • DIREct-On测定为优化NSCLC免疫疗法选择和管理提供了一个有前途的工具.
  • 这种方法可以通过早期识别可能达到持久反应的患者来改善治疗策略.